Trials / Completed
CompletedNCT04498390
A Safety Study of LY3493269 in Healthy Participants
A Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3493269 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3493269 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long it takes the body to eliminate it. For each participant, the study will last about 10 weeks and may include 12 visits, including five nights in a row in the clinical research center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3493269 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2020-09-03
- Primary completion
- 2020-12-28
- Completion
- 2020-12-28
- First posted
- 2020-08-04
- Last updated
- 2025-01-14
- Results posted
- 2025-01-14
Locations
1 site across 1 country: Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04498390. Inclusion in this directory is not an endorsement.